Drugs that contain Apalutamide

1. Drug name - ERLEADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9388159 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(7 years from now)

US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(10 years from now)

CN104619692A JANSSEN BIOTECH Crystalline Form Of Androgen Receptor Regulator
Oct, 2019

(2 years ago)

CN105693692A JANSSEN BIOTECH Crystalline Form Of Androgen Receptor Modulator
Sep, 2021

(1 year, 9 days ago)

CN101454002B JANSSEN BIOTECH For The Treatment Of Prostate Cancer And The Androgen Receptor-Related Disease Of Androgen Receptor Modulators
Mar, 2027

(4 years from now)

CN101454002A JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

IN200809025P1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Disease
Mar, 2027

(4 years from now)

IN283620B JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptorassociated Disease
Mar, 2027

(4 years from now)

EP2656841B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2004181A2 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656841A1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP3100727A1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656842B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2004181B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP3412290A1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656842A3 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656842A2 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP3100727B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP3412290B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2004181A4 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2368550A1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2368550B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2858985A4 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP3348553B1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP2858985B1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP3348553A1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP2858985A1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP3533792B1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP3533792A1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987261 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators Mar, 2027

(4 years from now)

US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases Mar, 2027

(4 years from now)

US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep, 2033

(10 years from now)

US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep, 2033

(10 years from now)

US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep, 2033

(10 years from now)

US10702508 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer Apr, 2038

(15 years from now)

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.